Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus
NCT01485614Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin A1C at 20 weeks, Number of Participants Who Experienced >=1 Adverse Event at 56 weeks and 1 more. Started Feb 2012; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01485614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485614.